Most Recent
Former Wallabies player Israel Folau has argued that the termination of his $5.7 million contract by a Rugby Australia Tribunal over social media posts in which he made a homphobic slur was an unreasonable restraint of trade.
Engineering firm WorleyParsons has told the Federal Court it will press forward with a no case application in an attempt to shut down a shareholder class action against it.
The Federal Court has partially struck out publisher Pan Macmillan Australia's defence in a defamation case brought by Sydney identity Thomas Domican over a "fleeting reference" in a book by nightclub magnate John Ibrahim.
One month after Japanese shipping company K-Line was hit with a $34.5 million fine for cartel conduct, Norwegian shipping firm Wallenius Wilhelmsen Ocean AS has said it will plead guilty to one charge of criminal cartel conduct for its role in the same scheme.
Concerns about duplicative costs in multiple class actions are better addressed by case management decisions aimed at cutting excessive expense, not by limiting the amount lawyers representing group members can spend, the Full Federal Court has said in dismissing an appeal by baby food maker Bellamy's.
Biotech company Cryosite has agreed to a $1 million settlement for losses resulting from legal advice received in relation to a merger agreement that left the company facing $1.05 million in penalties for engaging in cartel conduct.
Agricultural fund manager Rural Funds Group has briefed a top-tier law firm to bring “unprecedented” legal action against US company Bonitas Research, after the activist short seller accused the group of fraud and sent its share price plummeting.
WorleyParsons may seek to shut down a shareholder class action against it due to an "insuperable obstacle" caused by last minute pleading amendments, the engineering firm told a court at the outset of a 21-day hearing.
Two units of US pharmaceutical giant Pfizer have filed a lawsuit seeking damages from Juno Pharmaceuticals for allegedly infringing the patent for post-operative pain drug Dynastat.
Allianz Australia will refund over $8 million in fees and premiums to customers who were sold worthless cover they were not eligible to make claims under, including teenagers who were sold death cover.